Skip to content
ppharmaranks
Menu

Best Monoamine Oxidase Inhibitor for parkinson disease

Top-rated pick: Azilect — pharmaranks score 56/100, the highest of the 3 Monoamine Oxidase Inhibitor drugs used for parkinson disease, ranked by our independent FDA recall-safety score. Compare them with all treatments for parkinson disease or the full Monoamine Oxidase Inhibitor class. Not medical advice — always consult a professional.

Quick answer: Of the 3 monoamine oxidase inhibitor drugs we rate for parkinson disease, all are available as lower-cost generics, and most are tablet. Our ranking reflects each drug’s FDA recall-safety record — not clinical effectiveness for parkinson disease; the right choice depends on your situation, so confirm it with your prescriber.

Rated against independent regulatory sources·Last updated August 19, 2026·How we rate

Other drug classes for parkinson disease

Top monoamine oxidase inhibitor for parkinson disease: 1. Azilect · 2. Emsam · 3. Zelapar

Best-rated Monoamine Oxidase Inhibitor for parkinson disease, ranked by pharmaranks score
#DrugRatingPharmacy pays
156/100$30View →
2Not yet rated$20View →
3Not yet rated$20View →

Full ranking · 3 drugs

Frequently asked

What is the best monoamine oxidase inhibitor for parkinson disease?
By our independent recall-safety rating — not an efficacy measure — azilect ranks highest among Monoamine Oxidase Inhibitor drugs used for parkinson disease. Always consult a professional.
Which monoamine oxidase inhibitor drugs treat parkinson disease?
pharmaranks lists 3 Monoamine Oxidase Inhibitor products used for parkinson disease, per NIH RxClass drug-classification data — each independently rated and ranked above.
How are these ranked?
By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.